EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Chronic prurigo in an adolescent patient successfully controlled with dupilumab

Mohammed Nasser Al-Abdulla iD, Noof Al-Qahtani, Shahd M Younis, Syed Rizvi, Amro Elfaieg, Joerg Buddenkotte, Martin Steinhoff

Skin Health and Disease · 31.07.2026 · 6 (4) · 582-585

DOI: 10.1093/skinhd/vzag050 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Skin Health and Disease, online erschienen am 29.04.2026. Verfasst von Mohammed Nasser Al-Abdulla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamad Medical Corporation, Medical Research Center, Qatar National Library.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic prurigo, formerly termed prurigo nodularis, is a chronic skin condition characterized by intensely itchy nodules and papules. It primarily affects adults, particularly middle-aged women. The aetiology of chronic prurigo is unclear, but it can be associated with primary skin dermatoses and systemic conditions. Minimal data on chronic prurigo in children are available in the literature. While systemic therapies for chronic prurigo have significant side effects, targeted biologic and small-­molecule inhibitors offer a promising treatment option with a good benefit–risk ratio. We report one of the first cases of an adolescent with chronic prurigo that was successfully controlled with dupilumab. Dupilumab treatment resulted in a fast, significant and sustainable improvement in the signs and symptoms of chronic prurigo, with favourable safety and tolerability profiles, highlighting its potential for recalcitrant cases and long-term remission.

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.
  • Dermatology Institute, Hamad Medical Corporation, Doha, Qatar.
  • Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Weill Cornell Medicine-Qatar, School of Medicine, Doha, Qatar.
  • College of Medicine, Qatar University,Doha, Qatar.
  • Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.

ORCID-Profile: Mohammed Nasser Al-Abdulla

Förderung

  • Hamad Medical Corporation
  • Medical Research Center
  • Qatar National Library

Zitieren

APA

Al-Abdulla, M. N., Al-Qahtani, N., Younis, S. M., Rizvi, S., Elfaieg, A., Buddenkotte, J., & Steinhoff, M. (2026). Chronic prurigo in an adolescent patient successfully controlled with dupilumab. Skin Health and Disease, 6(4), 582-585. https://doi.org/10.1093/skinhd/vzag050

Vancouver

Al-Abdulla MN, Al-Qahtani N, Younis SM, Rizvi S, Elfaieg A, Buddenkotte J, et al. Chronic prurigo in an adolescent patient successfully controlled with dupilumab. Skin Health and Disease. 2026;6(4):582-585. doi:10.1093/skinhd/vzag050

BibTeX
@article{AlAbdulla2026,
  author = {Al-Abdulla, Mohammed Nasser and Al-Qahtani, Noof and Younis, Shahd M and Rizvi, Syed and Elfaieg, Amro and Buddenkotte, Joerg and Steinhoff, Martin},
  title = {Chronic prurigo in an adolescent patient successfully controlled with dupilumab},
  journal = {Skin Health and Disease},
  year = {2026},
  volume = {6},
  number = {4},
  pages = {582--585},
  doi = {10.1093/skinhd/vzag050}
}
Kostenlos starten →